Pharmaceuticals reported to induce P/P adverse events

This report will summarize scientific knowledge underlying the selection of a set of about 20 pharmaceuticals known for their ability to cause PP adverse effects in clinical use In order to have a diverse set of compounds they will be selected from different pharmacological classes 1 or 2 representative of each and therapeutic areas with either low molecular weight or biological structures Adverse events will be limited to behavioural domains associated with depression and suicidal ideation and behaviour which can be assessed in animals such as anhedonia aggression and impulsivity in addition to possible cognitive impairment Two additional pharmaceuticals devoid of the above adverse events serving as negative controls will also be selected The report will present the pharmacological profile of each compound primary and secondary targets the chemicalbiological structure the description of the adverse events nature incidence severity population in relation to PK in clinical setting and the preclinical findings in vitro in vivo wherever available This panel of compounds will be used to select the most appropriate ones for testing in the frame of Objective 22